Article

Pharmacological inhibition of CLK2 activates YAP by promoting alternative splicing of AMOTL2

2023-04-19

Abstract excerpt

Yes-associated protein (YAP), the downstream effector of the evolutionarily conserved Hippo pathway, promotes cellular proliferation and coordinates certain regenerative responses in mammals. Small molecule activators of YAP may therefore display therapeutic utility in treating disease states involving insufficient proliferative repair. From a high-throughput chemical screen of the comprehensive drug repurposing l...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4b020965-6d17-5870-83fe-54c5b85449f3
DOI: 10.1101/2023.04.19.537449

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Pharmacological inhibition of CLK2 activates YAP by promoting alternative splicing of AMOTL2DOI 10.1101/2023.04.19.537449Read

Specific CLK Inhibitors from a Novel Chemotype for Regulation of Alternative SplicingSemantic proximity Read

Manipulation of Alternative Splicing by a Newly Developed Inhibitor of ClksSemantic proximity Read

Anti‐tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC‐dependent vulnerabilitySemantic proximity Read

Small-molecule inhibition of Lats kinases promotes Yap-dependent proliferation in postmitotic mammalian tissuesSemantic proximity Read

CLK2 Is an Oncogenic Kinase and Splicing Regulator in Breast CancerSemantic proximity Read

An overview of cdc2‐like kinase 1 (Clk1) inhibitors and their therapeutic indicationsSemantic proximity Read

PKN2 Is a Dependency of the Mesenchymal-like Cancer Cell StateSemantic proximity Read

The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer modelsSemantic proximity Read

Pharmacological CLK inhibition disrupts SR protein function and RNA splicing blocking cell growth and migration in TNBCSemantic proximity Read

RNA processing kinase inhibitors and epigenetic inhibitors in combination with oncology drugs or investigational agents in multi-cell type patient-derived tumor cell line spheroidsSemantic proximity Read

Targeting the PI5P4K lipid kinase family in cancer using novel covalent inhibitorsSemantic proximity Read

Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancersSemantic proximity Read